We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+13.82%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.4B
AUM Growth
+$48.4M
Cap. Flow
+$23.3M
Cap. Flow %
1.66%
Top 10 Hldgs %
65.74%
Holding
68
New
19
Increased
7
Reduced
4
Closed
19

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$122M
2
NRIX icon
Nurix Therapeutics
NRIX
+$30M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14.6M
4
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$14M
5
KLRS
Kalaris Therapeutics
KLRS
+$13.3M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$69.1M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$40.6M
3
FATE icon
Fate Therapeutics
FATE
+$21.3M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$20.5M
5
DNLI icon
Denali Therapeutics
DNLI
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.9%
2 Miscellaneous 4.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
1
Xencor
XNCR
$1.94B
$176M 12.58%
4,547,072
– –
KURA icon
2
Kura Oncology
KURA
$1.13B
$141M 10.07%
4,608,529
– –
RLAY icon
3
Relay Therapeutics
RLAY
$4.11B
$136M 9.72%
+3,200,649
New +$122M
PRTA icon
4
Prothena Corp
PRTA
$479M
$94.2M 6.71%
9,426,640
– –
MORF
5
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$77.6M 5.54%
2,839,884
+1,911
+0.1% +$50.1K
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$77.1M 5.5%
464,298
+106,449
+30% +$14.6M
ORIC icon
7
Oric Pharmaceuticals
ORIC
$1.37B
$66.1M 4.71%
2,642,218
– –
RNAM
8
DELISTED
Avidity Biosciences
RNAM
$59.2M 4.22%
2,103,950
– –
ANAB icon
9
AnaptysBio
ANAB
$1.67B
$47.5M 3.39%
3,223,324
+148,310
+5% +$2.68M
NGNE icon
10
Neurogene
NGNE
$732M
$46.4M 3.31%
193,147
+16,313
+9% +$3.95M
AKUS
11
DELISTED
Akouos Inc
AKUS
$45.2M 3.22%
1,975,984
– –
ASMB icon
12
Assembly Biosciences
ASMB
$694M
$41.9M 2.99%
212,365
-50,451
-19% -$12.7M
NRIX icon
13
Nurix Therapeutics
NRIX
$2.72B
$41.6M 2.97%
+1,192,156
New +$30M
AMTI
14
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$36.6M 2.61%
1,150,000
– –
BCEL
15
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$33.9M 2.42%
2,426,685
+937,500
+63% +$14M
GERN icon
16
Geron
GERN
$970M
$33.5M 2.39%
19,230,769
– –
STRO icon
17
Sutro Biopharma
STRO
$339M
$31.3M 2.23%
311,362
+128,513
+70% +$12.1M
RCUS icon
18
Arcus Biosciences
RCUS
$3.72B
$31M 2.21%
1,810,000
– –
SURF
19
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$23M 1.64%
3,333,177
-1,700,684
-34% -$10.3M
CYCN icon
20
Cyclerion Therapeutics
CYCN
$17.7M
$16.7M 1.19%
137,114
– –
KLRS
21
Kalaris Therapeutics
KLRS
$95.9M
$12.3M 0.88%
+19,435
New +$13.3M
CBIO
22
Crescent Biopharma
CBIO
$659M
$11.4M 0.82%
37,252
+18,362
+97% +$7.02M
TNGX icon
23
Tango Therapeutics
TNGX
$3.94B
$8.29M 0.59%
+800,000
New +$8.17M
CNST
24
CALL
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$8.1M 0.58%
400,000
– –
VINC
25
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$7.82M 0.56%
+31,525
New +$6.41M
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2020 Portfolio in Review

As of Q3 2020, EcoR1 Capital held 68 positions worth $1.4B, up 3.6% from $1.35B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

EcoR1 Capital's Q3 2020 filing shows 19 new, 7 increased, 4 reduced and 19 closed positions. Its largest new stake was Relay Therapeutics: 3,200,649 shares worth $136M. The largest sale was Dicerna Pharmaceuticals, Inc., an estimated $69.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q3 2020 buy was Relay Therapeutics: 3,200,649 shares worth $136M.
  • EcoR1 Capital added most to Mirati Therapeutics, Inc. Common Stock in Q3 2020, an estimated $14.6M increase.
  • EcoR1 Capital's biggest Q3 2020 reduction was Assembly Biosciences, cutting an estimated $12.7M.
  • EcoR1 Capital fully exited Dicerna Pharmaceuticals, Inc. in Q3 2020, selling an estimated $69.1M.
  • EcoR1 Capital's ten largest holdings make up 66% of its $1.4B portfolio in Q3 2020.
  • EcoR1 Capital opened 19 new positions and closed 19 in Q3 2020.
  • EcoR1 Capital's portfolio value rose 3.6% quarter-over-quarter to $1.4B.

Based on EcoR1 Capital's 13F filing for Q3 2020, filed 16 Nov 2020.